Orexo AB Announces New Sales Figures for Abstral(TM) from Its Partner ProStrakan Group and Updates on the US Approval
11/16/2010 9:51:27 AM
UPPSALA, Sweden--(BUSINESS WIRE)--Regulatory News: Orexo AB (STO: ORX) announces that its sales partner in the EU and USA for Abstral™, ProStrakan Group plc (“ProStrakan”) yesterday issued its interim report, which gave further information on progress with Abstral™, Orexo’s leading sublingual fentanyl product for treatment of breakthrough cancer pain. Abstral™ recorded sales of £14.1m (156 MSEK) in the first 10 months of the year, representing growth of 345% over the corresponding period in 2009. In September 2010, ProStrakan launched Abstral™ in Italy which completes the roll-out of the product across the 5 major European markets.
comments powered by